Myasthenia gravis, autoimmune acquired (Q88653): Difference between revisions

← Older edit

@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/1205670816
@@ Property / Canonical URI: https://id.who.int/icd/entity/1205670816 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:ID_1205670816
@@ Property / CURIE: CID11:ID_1205670816 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-ID_1205670816
@@ Property / Canary Token: dki-india-ID_1205670816 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank

Latest revision as of 14:59, 15 August 2026

Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies.

Language	Label	Description	Also known as
default for all languages	ID_1205670816
English	Myasthenia gravis, autoimmune acquired	Acquired myasthenia gravis is an autoimmune disorder of the neuromuscular junction characterised by fluctuating muscular weakness that often affects selected muscle groups preferentially. The pathophysiological result is muscle endplate dysfunction and consequent fatigable weakness. Subtypes are broadly classified as: early-onset myasthenia gravis (<50 years); late-onset myasthenia gravis (>50 years); thymoma-associated myasthenia gravis; myasthenia gravis with anti-muscle-specific receptor tyrosine kinase antibodies; ocular myasthenia gravis; myasthenia gravis with no detectable antibodies.